1. Home
  2. DOMO vs MNMD Comparison

DOMO vs MNMD Comparison

Compare DOMO & MNMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DOMO
  • MNMD
  • Stock Information
  • Founded
  • DOMO 2010
  • MNMD 2019
  • Country
  • DOMO United States
  • MNMD United States
  • Employees
  • DOMO N/A
  • MNMD N/A
  • Industry
  • DOMO Computer Software: Prepackaged Software
  • MNMD Pharmaceuticals and Biotechnology
  • Sector
  • DOMO Technology
  • MNMD Health Care
  • Exchange
  • DOMO Nasdaq
  • MNMD Nasdaq
  • Market Cap
  • DOMO 562.5M
  • MNMD 509.2M
  • IPO Year
  • DOMO 2018
  • MNMD N/A
  • Fundamental
  • Price
  • DOMO $15.02
  • MNMD $9.30
  • Analyst Decision
  • DOMO Buy
  • MNMD Strong Buy
  • Analyst Count
  • DOMO 8
  • MNMD 7
  • Target Price
  • DOMO $15.13
  • MNMD $24.71
  • AVG Volume (30 Days)
  • DOMO 819.6K
  • MNMD 1.2M
  • Earning Date
  • DOMO 08-27-2025
  • MNMD 11-06-2025
  • Dividend Yield
  • DOMO N/A
  • MNMD N/A
  • EPS Growth
  • DOMO N/A
  • MNMD N/A
  • EPS
  • DOMO N/A
  • MNMD N/A
  • Revenue
  • DOMO $318,363,000.00
  • MNMD N/A
  • Revenue This Year
  • DOMO $1.78
  • MNMD N/A
  • Revenue Next Year
  • DOMO $2.66
  • MNMD N/A
  • P/E Ratio
  • DOMO N/A
  • MNMD N/A
  • Revenue Growth
  • DOMO N/A
  • MNMD N/A
  • 52 Week Low
  • DOMO $6.01
  • MNMD $4.70
  • 52 Week High
  • DOMO $17.88
  • MNMD $11.02
  • Technical
  • Relative Strength Index (RSI)
  • DOMO 51.01
  • MNMD 48.73
  • Support Level
  • DOMO $13.85
  • MNMD $8.70
  • Resistance Level
  • DOMO $17.88
  • MNMD $9.30
  • Average True Range (ATR)
  • DOMO 0.89
  • MNMD 0.58
  • MACD
  • DOMO -0.01
  • MNMD -0.11
  • Stochastic Oscillator
  • DOMO 37.31
  • MNMD 25.86

About DOMO Domo Inc. Class B

Domo Inc provides a cloud-based platform that digitally connects all the data, systems, and people in an organization, giving them access to real-time data and insights and allowing them to manage their business from their smartphones. The company offers a platform to its customers as a subscription-based service. Users receive notifications on any device and immediately act on the invitation, after which the system can write back to the original system of record. The company derives revenue from subscriptions to its cloud-based platform and professional services.

About MNMD Mind Medicine (MindMed) Inc.

Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).

Share on Social Networks: